SANTA BARBARA, CA – March 30, 2021 – CancerVax, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced it has closed its $2 million series A funding round. The Company intends to use the funds to begin work on its first immunotherapy cancer treatment. “We are grateful that we were able to rapidly close our initial funding,” said Lindsay Mann, CEO of CancerVax. Now we can complete our agreement with a top tier university to develop an immunotherapy treatment for a specific cancer. We expect to announce this commitment in the very near future.”
CancerVax, Inc. is developing immunotherapy cancer treatments that use the body’s immune system to fight cancer. Much like COVID-19 vaccines that train the body to recognize and destroy the coronavirus, we are developing cancer vaccines that train the body to target and destroy cancer cells. Our immunotherapy platform is aimed at creating lower cost personalized CAR T-cell therapies as well as generalized antibody treatments through nanotechnology and gene-editing innovations. For more information about the Company, please visit https://cancervax.com/.
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.